Exact Mass: 416.2383

Exact Mass Matches: 416.2383

Found 235 metabolites which its exact mass value is equals to given mass value 416.2383, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

Distigmine

(1-methylpyridin-1-ium-3-yl) N-methyl-N-[6-[methyl-(1-methylpyridin-1-ium-3-yl)oxycarbonylamino]hexyl]carbamate

C22H32N4O4 (416.2423)

ATC code: N07AA03

Atractyloside G

C21H36O8 (416.241)

Ramipril

Ramipril (Altace)

C23H32N2O5 (416.2311)

C - Cardiovascular system > C09 - Agents acting on the renin-angiotensin system > C09A - Ace inhibitors, plain > C09AA - Ace inhibitors, plain D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D000806 - Angiotensin-Converting Enzyme Inhibitors C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C471 - Enzyme Inhibitor > C783 - Protease Inhibitor > C247 - ACE Inhibitor D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS

Ramipril

(2S-(1(R*(r*)),2alpha,3abeta,6abeta))-1-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid

C23H32N2O5 (416.2311)

Ramipril is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to ramiprilat in the liver and, to a lesser extent, kidneys. Ramiprilat is a potent, competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Ramipril may be used in the treatment of hypertension, congestive heart failure, nephropathy, and to reduce the rate of death, myocardial infarction and stroke in individuals at high risk of cardiovascular events. C - Cardiovascular system > C09 - Agents acting on the renin-angiotensin system > C09A - Ace inhibitors, plain > C09AA - Ace inhibitors, plain D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D000806 - Angiotensin-Converting Enzyme Inhibitors C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C471 - Enzyme Inhibitor > C783 - Protease Inhibitor > C247 - ACE Inhibitor D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS

CPA(18:2(9Z,12Z)/0:0)

(2-Hydroxy-2-oxo-1,3,2λ⁵-dioxaphospholan-4-yl)methyl (9Z,12Z)-octadeca-9,12-dienoic acid

C21H37O6P (416.2328)

cPA(18:2(9Z,12Z)/0:0) is a cyclic phosphatidic acid or cyclic lysophosphatidic acid. It is a glycerophospholipid in which a cyclic phosphate moiety occupies two glycerol substitution sites. Lysophosphatidic acids can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1). Fatty acids containing 16 and 18 carbons are the most common. Cyclic phosphatidic acids have been detected in a wide range of organisms including humans, especially in the brain but also in serum (at a concentration of 10-7M). cPAs have a cyclic phosphate at the sn-2 and sn-3 positions of the glycerol carbons, and this structure is absolutely necessary for their activities. In particular, it is found in tissues subject to injury, and while it may have some similar signalling functions to lysophosphatidic acid per se, it also has some quite distinct biological activities. For example, cyclic phosphatidic acid is known to be a specific inhibitor of DNA polymerase alpha. It has an appreciable effect on the inhibition of cancer cell invasion and metastasis. [HMDB] cPA(18:2(9Z,12Z)/0:0) is a cyclic phosphatidic acid or cyclic lysophosphatidic acid. It is a glycerophospholipid in which a cyclic phosphate moiety occupies two glycerol substitution sites. Lysophosphatidic acids can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1). Fatty acids containing 16 and 18 carbons are the most common. Cyclic phosphatidic acids have been detected in a wide range of organisms including humans, especially in the brain but also in serum (at a concentration of 10-7M). cPAs have a cyclic phosphate at the sn-2 and sn-3 positions of the glycerol carbons, and this structure is absolutely necessary for their activities. In particular, it is found in tissues subject to injury, and while it may have some similar signalling functions to lysophosphatidic acid per se, it also has some quite distinct biological activities. For example, cyclic phosphatidic acid is known to be a specific inhibitor of DNA polymerase alpha. It has an appreciable effect on the inhibition of cancer cell invasion and metastasis.

Forasartan

5-[(dibutyl-1H-1,2,4-triazol-1-yl)methyl]-2-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]pyridine

C23H28N8 (416.2437)

Forasartan, a specific angiotensin II antagonist, is used alone or with other antihypertensive agents to treat hypertension. Forasartan competes with angiotensin II for binding at the AT1 receptor subtype. As angiotensin II is a vasoconstrictor which also stimulates the synthesis and release of aldosterone, blockage of its effects results in a decreases in systemic vascular resistance. C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C66930 - Angiotensin II Receptor Antagonist

Elarofiban

3-{[hydroxy({1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl})methylidene]amino}-3-(pyridin-3-yl)propanoate

C22H32N4O4 (416.2423)

Glutamylleucylarginine

4-Amino-4-({1-[(4-carbamimidamido-1-carboxybutyl)-C-hydroxycarbonimidoyl]-3-methylbutyl}-C-hydroxycarbonimidoyl)butanoate

C17H32N6O6 (416.2383)

Zabicipril

2-{2-[(1-ethoxy-1-oxo-4-phenylbutan-2-yl)amino]propanoyl}-2-azabicyclo[2.2.2]octane-3-carboxylic acid

C23H32N2O5 (416.2311)

AL 8810 Methyl ester

9,15R-dihydroxy-11-fluoro-15-(2,3-dihydro-1H-inden-2-yl)-16,17,18,19,20-pentanor-prosta-5Z,13E-dien-1-oic acid, methyl ester

C25H33FO4 (416.2363)

MMV688854

C24H28N6O (416.2324)

Distigmine

C22H32N4O4+2 (416.2423)

N - Nervous system > N07 - Other nervous system drugs > N07A - Parasympathomimetics > N07AA - Anticholinesterases D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D002800 - Cholinesterase Inhibitors D004791 - Enzyme Inhibitors

Ainsliaside D

C21H36O8 (416.241)

Kessyl glycol 8-O-glucoside

C21H36O8 (416.241)

Dihydrotentoxin

C22H32N4O4 (416.2423)

(5S,6E,10R)-5-beta-D-glucopyranosyloxy-3,10-dihydroxy-3,7,11-trimethyldodeca-1,5,11-triene|amarantholidoside II

C21H36O8 (416.241)

(1S,4S,5R,7R,10R)-11,14-dihydroxyguai-3-one 11-O-beta-D-glucopyranoside|(1S,4S,5R,7R,10R)-11,14-Dihydroxyguai-3-one 11-O-??-D-glucopyranoside|(1S,4S,5R,7R,10R)-11,14-dihydroxyguaian-3-one 11-O-beta-D-glucopyranoside

(1S,4S,5R,7R,10R)-11,14-dihydroxyguai-3-one 11-O-beta-D-glucopyranoside|(1S,4S,5R,7R,10R)-11,14-Dihydroxyguai-3-one 11-O-??-D-glucopyranoside|(1S,4S,5R,7R,10R)-11,14-dihydroxyguaian-3-one 11-O-beta-D-glucopyranoside

C21H36O8 (416.241)

foliachinenoside F

C21H36O8 (416.241)

foliachinenoside E

C21H36O8 (416.241)

(11S)-7-eudesmene-1beta,4beta,12-triol 1-O-beta-D-glucopyranose|iwayoside C

C21H36O8 (416.241)

(5Z)-6-[5-(2-beta-D-glucopyranosyloxy-propan-2-yl)-2-methyltetrahydrofuran-2-yl]-3-methylhexa-1,5-dien-3-ol|shanyeside B

C21H36O8 (416.241)

15-hydroxybisabolol oxide A beta-D-glucoside

C21H36O8 (416.241)

1-hydroperoxy-7,10-dihydroxybisabola-2,11-diene 7-beta-D-fucopyranoside

C21H36O8 (416.241)

1-hydroperoxy-7,12-dihydroxybisabola-2,10-diene 7-beta-D-fucopyranoside

C21H36O8 (416.241)

muurol-4-ene-1beta,3beta,10beta-triol 3-O-beta-D-glucopyranoside|rel-(2R,4aS,5R,8R,8aS)-1,2,4a,5,6,7,8,8a-octahydro-8,8a-dihydroxy-3,8-dimethyl-5-(1-methylethyl)naphthalen-2-yl beta-D-glucopyranoside

C21H36O8 (416.241)

muurol-4-ene-1beta,3beta,15-triol 3-O-beta-D-glucopyranoside|rel-(2R,4aS,5R,8S,8aR)-1,2,4a,5,6,7,8,8a-octahydro-8a-hydroxy-3-(hydroxymethyl)-8-methyl-5-(1-methylethyl)naphthalen-2-yl beta-D-glucopyranoside

muurol-4-ene-1beta,3beta,15-triol 3-O-beta-D-glucopyranoside|rel-(2R,4aS,5R,8S,8aR)-1,2,4a,5,6,7,8,8a-octahydro-8a-hydroxy-3-(hydroxymethyl)-8-methyl-5-(1-methylethyl)naphthalen-2-yl beta-D-glucopyranoside

C21H36O8 (416.241)

beta-methyl-15-hydroxymethylfaurinone-9-alpha-O-beta-D-glucoside|cupressusoside

C21H36O8 (416.241)

(5Z)-6-[5-(2-hydroxypropan-2-yl)-2-methyltetrahydrofuran-2-yl]-3-methylhexa-1,5-dien-3-O-beta-D-glucopyranoside

C21H36O8 (416.241)

(5S,6E,9E)-5-beta-D-glucopyranosyloxy-3,11-dihydroxy-3,7,11-trimethyldodeca-1,6,9-triene|amarantholidoside I

C21H36O8 (416.241)

1beta,6beta,9alpha-trihydroxy-trans-eudesm-3-ene-6-O-beta-D-glucopyranoside

C21H36O8 (416.241)

erigeside A

C21H36O8 (416.241)

1-acetyl-15,16-dimethoxy-aspidospermidine-17,21-diol|N-Acetyl-N-depropionyl-aspido-albinol

C23H32N2O5 (416.2311)

Glycosarcostin

C21H36O8 (416.241)

erythronolide H

C21H36O8 (416.241)

2alpha,7-dihydroxykessane 2-O-beta-D-glucopyranoside

C21H36O8 (416.241)

Trp Val Ile

C22H32N4O4 (416.2423)

Arg Ile Glu

C17H32N6O6 (416.2383)

Glu Arg Ile

C17H32N6O6 (416.2383)

Val Ile Trp

C22H32N4O4 (416.2423)

Ile Val Trp

C22H32N4O4 (416.2423)

Arg Asp Leu

C17H32N6O6 (416.2383)

Ile Arg Glu

C17H32N6O6 (416.2383)

glutamylisoleucylarginine

C17H32N6O6 (416.2383)

Asp Arg Leu

C17H32N6O6 (416.2383)

Val Trp Ile

C22H32N4O4 (416.2423)

Arg Glu Ile

C17H32N6O6 (416.2383)

isoleucylglutamylarginine

C17H32N6O6 (416.2383)

Leu Arg Asp

C17H32N6O6 (416.2383)

Ile Trp Val

C22H32N4O4 (416.2423)

Asp Leu Arg

C17H32N6O6 (416.2383)

Ala Ala Lys Gln

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-aminopropanamido]propanamido]hexanamido]-4-carbamoylbutanoic acid

C17H32N6O6 (416.2383)

Ala Ala Gln Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S)-2-aminopropanamido]propanamido]-4-carbamoylbutanamido]hexanoic acid

C17H32N6O6 (416.2383)

Ala Lys Ala Gln

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-aminopropanamido]hexanamido]propanamido]-4-carbamoylbutanoic acid

C17H32N6O6 (416.2383)

Ala Lys Gln Ala

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-aminopropanamido]hexanamido]-4-carbamoylbutanamido]propanoic acid

C17H32N6O6 (416.2383)

Ala Gln Ala Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S)-2-aminopropanamido]-4-carbamoylbutanamido]propanamido]hexanoic acid

C17H32N6O6 (416.2383)

Ala Gln Lys Ala

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-aminopropanamido]-4-carbamoylbutanamido]hexanamido]propanoic acid

C17H32N6O6 (416.2383)

Gly Lys Asn Val

(2S)-2-[(2S)-2-[(2S)-6-amino-2-(2-aminoacetamido)hexanamido]-3-carbamoylpropanamido]-3-methylbutanoic acid

C17H32N6O6 (416.2383)

Gly Lys Val Asn

(2S)-2-[(2S)-2-[(2S)-6-amino-2-(2-aminoacetamido)hexanamido]-3-methylbutanamido]-3-carbamoylpropanoic acid

C17H32N6O6 (416.2383)

Gly Asn Lys Val

(2S)-2-[(2S)-6-amino-2-[(2S)-2-(2-aminoacetamido)-3-carbamoylpropanamido]hexanamido]-3-methylbutanoic acid

C17H32N6O6 (416.2383)

Gly Asn Val Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-(2-aminoacetamido)-3-carbamoylpropanamido]-3-methylbutanamido]hexanoic acid

C17H32N6O6 (416.2383)

Gly Val Lys Asn

(2S)-2-[(2S)-6-amino-2-[(2S)-2-(2-aminoacetamido)-3-methylbutanamido]hexanamido]-3-carbamoylpropanoic acid

C17H32N6O6 (416.2383)

Gly Val Asn Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-(2-aminoacetamido)-3-methylbutanamido]-3-carbamoylpropanamido]hexanoic acid

C17H32N6O6 (416.2383)

Glu Ile Arg

C17H32N6O6 (416.2383)

Arg Glu Leu

C17H32N6O6 (416.2383)

Trp Leu Val

C22H32N4O4 (416.2423)

Val Leu Trp

C22H32N4O4 (416.2423)

Lys Ala Ala Gln

(2S)-4-carbamoyl-2-[(2S)-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]propanamido]propanamido]butanoic acid

C17H32N6O6 (416.2383)

Lys Ala Gln Ala

(2S)-2-[(2S)-4-carbamoyl-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]propanamido]butanamido]propanoic acid

C17H32N6O6 (416.2383)

Lys Gly Asn Val

(2S)-2-[(2S)-3-carbamoyl-2-{2-[(2S)-2,6-diaminohexanamido]acetamido}propanamido]-3-methylbutanoic acid

C17H32N6O6 (416.2383)

Lys Gly Val Asn

(2S)-3-carbamoyl-2-[(2S)-2-{2-[(2S)-2,6-diaminohexanamido]acetamido}-3-methylbutanamido]propanoic acid

C17H32N6O6 (416.2383)

Lys Asn Gly Val

(2S)-2-{2-[(2S)-3-carbamoyl-2-[(2S)-2,6-diaminohexanamido]propanamido]acetamido}-3-methylbutanoic acid

C17H32N6O6 (416.2383)

Lys Asn Val Gly

2-[(2S)-2-[(2S)-3-carbamoyl-2-[(2S)-2,6-diaminohexanamido]propanamido]-3-methylbutanamido]acetic acid

C17H32N6O6 (416.2383)

Lys Gln Ala Ala

(2S)-2-[(2S)-2-[(2S)-4-carbamoyl-2-[(2S)-2,6-diaminohexanamido]butanamido]propanamido]propanoic acid

C17H32N6O6 (416.2383)

Lys Val Gly Asn

(2S)-3-carbamoyl-2-{2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-3-methylbutanamido]acetamido}propanoic acid

C17H32N6O6 (416.2383)

Lys Val Asn Gly

2-[(2S)-3-carbamoyl-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-3-methylbutanamido]propanamido]acetic acid

C17H32N6O6 (416.2383)

Leu Trp Val

C22H32N4O4 (416.2423)

Leu Val Trp

C22H32N4O4 (416.2423)

Ile Glu Arg

C17H32N6O6 (416.2383)

Trp Ile Val

C22H32N4O4 (416.2423)

Asn Gly Lys Val

(2S)-2-[(2S)-6-amino-2-{2-[(2S)-2-amino-3-carbamoylpropanamido]acetamido}hexanamido]-3-methylbutanoic acid

C17H32N6O6 (416.2383)

Asn Gly Val Lys

(2S)-6-amino-2-[(2S)-2-{2-[(2S)-2-amino-3-carbamoylpropanamido]acetamido}-3-methylbutanamido]hexanoic acid

C17H32N6O6 (416.2383)

Asn Lys Gly Val

(2S)-2-{2-[(2S)-6-amino-2-[(2S)-2-amino-3-carbamoylpropanamido]hexanamido]acetamido}-3-methylbutanoic acid

C17H32N6O6 (416.2383)

Asn Lys Val Gly

2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-amino-3-carbamoylpropanamido]hexanamido]-3-methylbutanamido]acetic acid

C17H32N6O6 (416.2383)

Arg Leu Glu

C17H32N6O6 (416.2383)

Asn Val Gly Lys

(2S)-6-amino-2-{2-[(2S)-2-[(2S)-2-amino-3-carbamoylpropanamido]-3-methylbutanamido]acetamido}hexanoic acid

C17H32N6O6 (416.2383)

Asn Val Lys Gly

2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-amino-3-carbamoylpropanamido]-3-methylbutanamido]hexanamido]acetic acid

C17H32N6O6 (416.2383)

Val Trp Leu

C22H32N4O4 (416.2423)

Leu Arg Glu

C17H32N6O6 (416.2383)

Gln Ala Ala Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-carbamoylbutanamido]propanamido]propanamido]hexanoic acid

C17H32N6O6 (416.2383)

Gln Ala Lys Ala

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-amino-4-carbamoylbutanamido]propanamido]hexanamido]propanoic acid

C17H32N6O6 (416.2383)

Gln Lys Ala Ala

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-amino-4-carbamoylbutanamido]hexanamido]propanamido]propanoic acid

C17H32N6O6 (416.2383)

Leu Glu Arg

C17H32N6O6 (416.2383)

Trp Val Leu

C22H32N4O4 (416.2423)

Glu Leu Arg

C17H32N6O6 (416.2383)

Glu Arg Leu

C17H32N6O6 (416.2383)

Val Gly Lys Asn

(2S)-2-[(2S)-6-amino-2-{2-[(2S)-2-amino-3-methylbutanamido]acetamido}hexanamido]-3-carbamoylpropanoic acid

C17H32N6O6 (416.2383)

Val Gly Asn Lys

(2S)-6-amino-2-[(2S)-2-{2-[(2S)-2-amino-3-methylbutanamido]acetamido}-3-carbamoylpropanamido]hexanoic acid

C17H32N6O6 (416.2383)

Val Lys Gly Asn

(2S)-2-{2-[(2S)-6-amino-2-[(2S)-2-amino-3-methylbutanamido]hexanamido]acetamido}-3-carbamoylpropanoic acid

C17H32N6O6 (416.2383)

Val Lys Asn Gly

2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-amino-3-methylbutanamido]hexanamido]-3-carbamoylpropanamido]acetic acid

C17H32N6O6 (416.2383)

Val Asn Gly Lys

(2S)-6-amino-2-{2-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]-3-carbamoylpropanamido]acetamido}hexanoic acid

C17H32N6O6 (416.2383)

Val Asn Lys Gly

2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]-3-carbamoylpropanamido]hexanamido]acetic acid

C17H32N6O6 (416.2383)

CPA(18:2)

1-(9Z,12Z-Octadecadienoyl)-cyclophosphatidic acid

C21H37O6P (416.2328)

Forasartan

5-[(dibutyl-1H-1,2,4-triazol-1-yl)methyl]-2-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]pyridine

C23H28N8 (416.2437)

C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C66930 - Angiotensin II Receptor Antagonist

R 121919 hydrochloride

C22H33ClN6 (416.2455)

1-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-((2-(triMethylsilyl)ethoxy)Methyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)ethanone

C21H33BN2O4Si (416.2303)

1-BOC-4-[4-(4,4,5,5-TETRAMETHYL-[1,3,2]DIOXABOROLAN-2-YL)-BENZOYL]-PIPERAZINE

C22H33BN2O5 (416.2482)

tert-butyl 4-[[2-(5-amino-3-methyl-1H-pyrazol-4-yl)-6-methoxy-phe noxy]methyl]piperidine-1-carboxylate

C22H32N4O4 (416.2423)

4-O-ACETYL-3 6-DI-O-(TERT-BUTYLDIMETHYL&

C20H40O5Si2 (416.2414)

Zabicipril

C23H32N2O5 (416.2311)

BS-181 hydrochloride

C22H33ClN6 (416.2455)

diphenyl tridecyl phosphite

C25H37O3P (416.248)

tert-Butyl 4-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoyl)piperazine-1-carboxylate

C22H33BN2O5 (416.2482)

Tonapofylline

C22H32N4O4 (416.2423)

C78273 - Agent Affecting Respiratory System > C29712 - Anti-asthmatic Agent > C319 - Bronchodilator Tonapofylline (BG 9928) is an orally active and selective adenosine A1 receptor antagonist with a Ki of 7.4 nM for human adenosine A1 receptor (hA1), which displays 915-fold selectivity versus human adenosine A2A receptor and 12-fold selectivity versus human adenosine A2B receptor and is used in development for the treatment of heart failure[1][2].

(2S,3aR,6aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-1-oxopropyl]-3,3a,4,5,6,6a-hexahydro-2H-cyclopenta[b]pyrrole-2-carboxylic acid

C23H32N2O5 (416.2311)

3-(6-ethoxynaphthalen-2-yl)-1-((1-methylpiperidin-4-yl)methyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine

C24H28N6O (416.2324)

(3aS,6aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-1-oxopropyl]-3,3a,4,5,6,6a-hexahydro-2H-cyclopenta[b]pyrrole-2-carboxylic acid

C23H32N2O5 (416.2311)

Leu-Val-Trp

C22H32N4O4 (416.2423)

5-Benzyl-2,3-bis(4-methoxyphenyl)-1,4-dimethylpiperazine

C27H32N2O2 (416.2464)

1-(9Z,12Z)-octadecadienylglycerone 3-phosphate(2-)

C21H37O6P-2 (416.2328)

3-[[(1,3-dimethyl-4-pyrazolyl)methyl-methylamino]methyl]-N-methyl-N-(phenylmethyl)-2-imidazo[1,2-a]pyridinecarboxamide

C24H28N6O (416.2324)

Arg-Leu-Glu

C17H32N6O6 (416.2383)

Glu-Arg-Leu

C17H32N6O6 (416.2383)

Leu-Arg-Glu

C17H32N6O6 (416.2383)

Glutamyl-leucyl-arginine

C17H32N6O6 (416.2383)

Ile-Arg-Glu

C17H32N6O6 (416.2383)

Leu-Glu-Arg

C17H32N6O6 (416.2383)

N-[(2S,3R,6R)-6-[2-(3,4-dihydro-1H-isoquinolin-2-yl)-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]-4-oxanecarboxamide

C23H32N2O5 (416.2311)

N-[(2R,3R,6R)-6-[2-(3,4-dihydro-1H-isoquinolin-2-yl)-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]-4-oxanecarboxamide

C23H32N2O5 (416.2311)

N-[(2R,3R,6S)-6-[2-(3,4-dihydro-1H-isoquinolin-2-yl)-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]-4-oxanecarboxamide

C23H32N2O5 (416.2311)

N-[(2S,3R,6S)-6-[2-(3,4-dihydro-1H-isoquinolin-2-yl)-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]-4-oxanecarboxamide

C23H32N2O5 (416.2311)

N-[(2R,3S,6R)-6-[2-(3,4-dihydro-1H-isoquinolin-2-yl)-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]-4-oxanecarboxamide

C23H32N2O5 (416.2311)

N-[(2R,3S,6S)-6-[2-(3,4-dihydro-1H-isoquinolin-2-yl)-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]-4-oxanecarboxamide

C23H32N2O5 (416.2311)

N-[(2S,3S,6S)-6-[2-(3,4-dihydro-1H-isoquinolin-2-yl)-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]-4-oxanecarboxamide

C23H32N2O5 (416.2311)

N-[(2S,3S,6R)-6-[2-(3,4-dihydro-1H-isoquinolin-2-yl)-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]-4-oxanecarboxamide

C23H32N2O5 (416.2311)

2-[(3R,6aS,8S,10aS)-3-hydroxy-1-(1-oxo-2-phenylethyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-cyclobutylacetamide

C23H32N2O5 (416.2311)

Val-Trp-Ile

C22H32N4O4 (416.2423)

Arg-Ile-Glu

C17H32N6O6 (416.2383)

Leu-Trp-Val

C22H32N4O4 (416.2423)

Trp-Val-Ile

C22H32N4O4 (416.2423)

Val-Ile-Trp

C22H32N4O4 (416.2423)

Trp-Val-Leu

C22H32N4O4 (416.2423)

Val-Leu-Trp

C22H32N4O4 (416.2423)

Glu-Ile-Arg

C17H32N6O6 (416.2383)

Ile-Val-Trp

C22H32N4O4 (416.2423)

Arg-Glu-Ile

C17H32N6O6 (416.2383)

Arg-Glu-Leu

C17H32N6O6 (416.2383)

Glu-Arg-Ile

C17H32N6O6 (416.2383)

Ile-Glu-Arg

C17H32N6O6 (416.2383)

Ile-Trp-Val

C22H32N4O4 (416.2423)

Trp-Ile-Val

C22H32N4O4 (416.2423)

Trp-Leu-Val

C22H32N4O4 (416.2423)

Val-Trp-Leu

C22H32N4O4 (416.2423)

1-(9Z,12Z,15Z)-octadecatrienylglycerone 3-phosphate

C21H37O6P (416.2328)

A 1-alkylglycerone 3-phosphate in which the alkyl group is specified as (9Z,12Z,15Z)-octadecatrienyl.

Ramipril (Altace)

C23H32N2O5 (416.2311)

CID 168510744

C17H32N6O6 (416.2383)

CPA(18:2(9Z,12Z)/0:0)

C21H37O6P (416.2328)

1-(9Z,12Z)-octadecadienylglycerone 3-phosphate(2-)

C21H37O6P (416.2328)

A 1-alkylglycerone 3-phosphate(2-) obtained by deprotonation of the phosphate OH groups of 1-(9Z,12Z)-octadecadienylglycerone 3-phosphate; major species at pH 7.3.

Glu-Leu-Arg

C17H32N6O6 (416.2383)

ST 21:0;O8

C21H36O8 (416.241)

(3s,6s,12s)-12-benzyl-5,11-dihydroxy-1,6,7-trimethyl-3-(2-methylpropyl)-1,4,7,10-tetraazacyclododeca-4,10-diene-2,8-dione

C22H32N4O4 (416.2423)

(2s,3r,4s,5s,6r)-2-{[(1s,2s,4ar,6r,7s,8ar)-1,6-dihydroxy-1,4a-dimethyl-7-(prop-1-en-2-yl)-octahydronaphthalen-2-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C21H36O8 (416.241)

(2r,3r,4s,5s,6r)-2-{[(1s,1ar,3ar,4s,7r,7as,7bs)-4-hydroxy-1-(hydroxymethyl)-1,7-dimethyl-octahydro-1ah-cyclopropa[a]naphthalen-4-yl]methoxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C21H36O8 (416.241)

(2r,3s,4s,5s,6s)-2-{[(1r,1ar,4s,4as,7r,7as,7bs)-4-hydroxy-1-(hydroxymethyl)-1,7-dimethyl-octahydro-1ah-cyclopropa[e]azulen-4-yl]methoxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C21H36O8 (416.241)

2-{[2-(6,7-dihydroxy-4a-methyl-8-methylidene-octahydronaphthalen-2-yl)propan-2-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C21H36O8 (416.241)

2-{[1,6-dihydroxy-1,4a-dimethyl-7-(prop-1-en-2-yl)-octahydronaphthalen-2-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C21H36O8 (416.241)

(1s,3as,4r,7r,8ar)-4-(hydroxymethyl)-1-methyl-7-(2-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}propan-2-yl)-octahydro-1h-azulen-2-one

C21H36O8 (416.241)

2-{[2,4-dihydroxy-4,8a-dimethyl-6-(prop-1-en-2-yl)-octahydronaphthalen-1-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C21H36O8 (416.241)

(2r,3r,4s,5s,6r)-2-{[(3s,5s,6e,9e)-3,11-dihydroxy-3,7,11-trimethyldodeca-1,6,9-trien-5-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C21H36O8 (416.241)

10β,13,14-trihydroxyalloaromadendrane

C21H36O8 (416.241)

{"Ingredient_id": "HBIN000059","Ingredient_name": "10\u03b2,13,14-trihydroxyalloaromadendrane","Alias": "NA","Ingredient_formula": "C21H36O8","Ingredient_Smile": "CC1CCC2C1C3C(C3(C)CO)CCC2(COC4C(C(C(C(O4)CO)O)O)O)O","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "42560","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

(1s,4s,5r,7r,10r)-11,14-dihydroxyguai-3-one11-o-β-d-glucopyranoside

C21H36O8 (416.241)

{"Ingredient_id": "HBIN003289","Ingredient_name": "(1s,4s,5r,7r,10r)-11,14-dihydroxyguai-3-one11-o-\u03b2-d-glucopyranoside","Alias": "NA","Ingredient_formula": "C21H36O8","Ingredient_Smile": "CC1C2CC(CCC(C2CC1=O)CO)C(C)(C)OC3C(C(C(C(O3)CO)O)O)O","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "SMIT15108","TCMID_id": "5901","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

alatoside a

C21H36O8 (416.241)

{"Ingredient_id": "HBIN015044","Ingredient_name": "alatoside a","Alias": "NA","Ingredient_formula": "C21H36O8","Ingredient_Smile": "CC(=C)C1CCC2(C(C1)C(CC(C2OC3C(C(C(C(O3)CO)O)O)O)O)(C)O)C","Ingredient_weight": "416.5 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "838","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "11144190","DrugBank_id": "NA"}

atractyloside g

C21H36O8 (416.241)

{"Ingredient_id": "HBIN017307","Ingredient_name": "atractyloside g","Alias": "NA","Ingredient_formula": "C21H36O8","Ingredient_Smile": "CC12CCC(CC1C(=C)C(C(C2)O)O)C(C)(C)OC3C(C(C(C(O3)CO)O)O)O","Ingredient_weight": "416.5 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "SMIT14423","TCMID_id": "1979","TCMSP_id": "NA","TCM_ID_id": "6487","PubChem_id": "101831405","DrugBank_id": "NA"}